IP Library Granted Patent US 9,821,041
Granted Patent B2
US 9,821,041 · App. 14/843,751 · Granted Nov 21, 2017

Crystallized oxalate decarboxylase and methods of use

Inventors: Bhami C. Shenoy (South Grafton, MA); Teresa G. Cachero (Hingham, MA); John Shin (Burlington, MA); Lekai Zhang (Watertown, MA); Aftab Rashid (Natick, MA); Danica Grujic (Boston, MA); Reena J. Patel (Woburn, MA); Margaret Ellen McGrath (Somerville, MA)
Assignee: Allena Pharmaceuticals, Inc.
A61K38/51A61K9/0034A61M1/16A61M1/3687C12N9/88C12Q1/527A61K38/00A61M2202/0413A61M2205/75C07K2299/00C12Y401/01002G01N2333/988
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,821,041
App. No.
14/843,751
Granted
Nov 21, 2017
Kind
B2
Abstract

Oxalate decarboxylase crystals, including stabilized crystals, such as cross-linked crystals of oxalate decarboxylase, are disclosed. Methods to treat a disorder associated with elevated oxalate concentration using oxalate decarboxylase crystals are also disclosed. Additionally disclosed are methods of producing protein crystals.

Claims (9)

1. A pharmaceutical composition comprising spray-dried biologically active oxalate decarboxylase crystals having a moisture content of less than 5% by weight, wherein the oxalate decarboxylase is uncrosslinked and is capable of converting oxalate to formate.

2. The pharmaceutical composition of claim 1 , wherein the oxalate decarboxylase crystals are about 1 μm to about 25 μm in length.

3. The pharmaceutical composition of claim 1 , further comprising at least one excipient selected from a sugar, sugar alcohol, viscosity increasing agent, wetting agent, solubilizing agent, buffer salt, emulsifying agent, antimicrobial agent, and an antioxidant.

4. The pharmaceutical composition of claim 1 , wherein the composition is an oral dosage form.

5. The pharmaceutical composition of claim 4 , wherein the oral dosage form is formulated as a capsule.

6. The pharmaceutical composition of claim 4 , wherein the oral dosage form is formulated as a tablet.

7. The pharmaceutical composition of claim 1 , wherein the oxalate decarboxylase retains at least 50% of its activity upon exposure to an aqueous solution having a pH of about 6.8 for 1 hour.

8. The pharmaceutical composition of claim 1 , wherein the oxalate decarboxylase is a recombinant oxalate decarboxylase.

9. The pharmaceutical composition of claim 1 , wherein the oxalate decarboxylase has an amino acid sequence which has at least 95% sequence identity with SEQ ID NO: 3.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2023
From: ALLENA PHARMACEUTICALS
To: GLYSCEND, INC.
Reel/Frame 065554/0212 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2017
From: AJINOMOTO ALTHEA, INC.
To: ALLENA PHARMACEUTICALS, INC.
Reel/Frame 043038/0643 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2016
From: SHENOY, BHAMI C.; CACHERO, TERESA G.; SHIN, JOHN; ZHANG, LEKAI; RASHID, AFTAB; GRUJIC, DANICA; PATEL, REENA J.; MCGRATH, MARGARET ELLEN
To: ALTUS PHARMACEUTICALS, INC.
Reel/Frame 037666/0716 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2016
From: LYNNE F. RILEY, AS CHAPTER 7 TRUSTEE OF ALTUS PHARMACEUTICALS, INC.
To: ALTHEA TECHNOLOGIES, INC.
Reel/Frame 037666/0809 →
CHANGE OF NAME Recorded Feb 4, 2016
From: ALTHEA TECHNOLOGIES, INC.
To: AJINOMOTO ALTHEA, INC.
Reel/Frame 037697/0078 →
Continuity (6)
Division 14283794 · May 21, 2014
Continuation 13372274 · Feb 13, 2012
Division 11833082 · Aug 2, 2007
Provisional Application 60854540 · Oct 26, 2006
Provisional Application 60834933 · Aug 2, 2006
Related Publication 20160051647A1 · Feb 25, 2016